INS and Hypoglycemia: Together, these data confirm guidelines recommendations [45] to consider GLP1-RA therapy as an injective alternative to insulin therapy in patients not achieving treatment targets, allowing extended metabolic control associated with cardio-protection and weight loss, without the risks associated with hypoglycemia and possible weight gain deriving from the use of insulin.